Drug Patent Watch

DECEMBER 9, 2024

In the vast realm of pharmaceutical research and development, there’s a fascinating intersection between ancient wisdom and modern science. This intersection is where pharmacognosy meets drug patents, creating a unique landscape that shapes the future of medicine.

Medicine 97

Medicine Drugs Production Development 97

Bio Pharma Dive

OCTOBER 24, 2023

Rampart Biosciences closed a Series A round that will fund its goal to develop more potent DNA-based medicines that avoid immune responses.

DNA 270

DNA Medicine Immune Response Development 270

Bio Pharma Dive

DECEMBER 10, 2023

A new sickle cell disease therapy developed by CRISPR Therapeutics and Vertex Pharmaceuticals is now approved in the U.S. This is the story of how it came to be.

Medicine 356

Medicine Development 356

Bio Pharma Dive

MAY 2, 2022

The regulator cited concerns around single-country trials in turning back Hutchmed's pancreatic cancer treatment, while manufacturing issues held up Junshi and Coherus' throat cancer medicine.

Development 327

Development Regulation Manufacturing Drugs 327

Rethinking Clinical Trials

MARCH 4, 2025

The article was published online in Statistics in Medicine. The post March 4, 2025: PRIM-ER Team Develops Innovative Statistical Techniques for Stepped-Wedge Trials appeared first on Rethinking Clinical Trials. The study was supported by the National Institute on Aging. Learn more about PRIM-ER.

Trials 170

Trials Development Contamination Clinical Trials 170

Bio Pharma Dive

OCTOBER 30, 2023

The venture firm has supported a number of approved medicines with its co-development strategy, including Pfizer’s Besponsa and Apellis’ Empaveli.

Development 271

Development Medicine Drugs 271

Pharmaceutical Technology

OCTOBER 22, 2024

Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal worth $283m.

Gene Editing 244

Gene Editing Gene Development Medicine 244

Pharmaceutical Technology

OCTOBER 28, 2022

Drug discovery and development is an incredibly expensive and time-consuming process, taking between 12 and 18 years, and costing on average between $2 billion and $3 billion. Robots can improve drug discovery and development. Lab-specific industrial co-bots can carry out both complex and repetitive tasks such as liquid handling.

Development 311

Development Drugs Pharma Companies Life Science 311

Pharmaceutical Technology

SEPTEMBER 21, 2023

Kezar and Everest Medicines have signed a deal for the development and commercialisation of zetomipzomib for lupus nephritis.

Development 246

Development Medicine 246

Bio Pharma Dive

MARCH 28, 2023

The biotech is working on a dual-acting weight loss treatment that could compete with medicines from Novo Nordisk, Eli Lilly and others.

Development 323

Development Medicine Drugs 323

Drug Patent Watch

DECEMBER 11, 2024

This article outlines key considerations and strategies for developing a sustainable generic drug development strategy. Pfizer, for example, has been applying green chemistry principles in drug development for over two decades to reduce waste, minimize resource use, and develop energy-efficient manufacturing processes.

Generic Drugs 98

Generic Drugs Development Drugs Compliance 98

AuroBlog - Aurous Healthcare Clinical Trials blog

SEPTEMBER 30, 2024

Researchers see a greater need for new generation therapeutics to propel precision medicine. The development of innovative therapeutic approaches in healthcare encompass a variety of fields, including gene therapy, personalized medicine, immunotherapy, and advanced biologics.

Medicine 189

Medicine Research Gene Therapy Genetics 189

Bio Pharma Dive

AUGUST 2, 2022

Founded by serial entrepreneur Alexis Borisy, the company comes equipped with two experimental medicines it licensed from Merck KGaA and Blueprint Medicines.

Licensing 310

Licensing Licensing Development Medicine 310

Bio Pharma Dive

NOVEMBER 17, 2022

While the biotech will not develop the gene editing therapy further on its own, CEO Gilmore O’Neill claimed the data are still a meaningful demonstration of what CRISPR can accomplish.

Gene Editing 309

Gene Editing Medicine Gene Development 309

Drug Patent Watch

JANUARY 23, 2025

The Future of Generic Drug Development: Opportunities and Challenges for Emerging Markets As the global healthcare landscape continues to evolve, emerging markets are playing an increasingly important role in shaping the future of generic drug development.

Generic Drugs 85

Generic Drugs Marketing Development Drugs 85

Bio Pharma Dive

JULY 12, 2023

Backed by F-Prime Capital and Sofinnova Partners, the company claims to have technology that could allow it replace eye cells destroyed in age-related and inherited ocular conditions.

Medicine 234

Medicine Development 234

Pharmaceutical Technology

JUNE 1, 2023

A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drug delivery technologies. The funding is being provided under the agency’s Transforming Medicines Manufacturing programme.

Drug Delivery 242

Drug Delivery RNA Development Drugs 242

Pharmaceutical Technology

OCTOBER 19, 2022

Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of precision genetic medicine firm Akouos for a total deal value of up to nearly $610m or up to $15.50 Akouos focuses on developing adeno-associated viral gene therapies to treat inner ear conditions, including sensorineural hearing loss.

Gene Therapy 298

Gene Therapy Gene Development Genetics 298

Pharmaceutical Technology

DECEMBER 15, 2022

Eisai has entered a comprehensive research partnership agreement with Washington University School of Medicine in St Louis, US, to develop potential new therapies for neurodegenerative ailments. Under the deal, the parties intend to develop treatments for diseases including Alzheimer’s and Parkinson’s.

Development 246

Development Medicine Sales Scientist 246

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The partnership will focus on developing potential new vaccines to treat certain selected autoimmune indications, as well as food allergies.

Vaccine 245

Vaccine Vaccination Development Allergies 245

Pharmaceutical Technology

MAY 17, 2023

Chinook Therapeutics and Ionis Pharmaceuticals have entered a partnership to develop an antisense oligonucleotide (ASO) therapy to treat a rare, severe chronic kidney disease. The collaboration aims to discover, develop and commercialise an ASO therapy.

Development 246

Development Protein RNA Genetics 246

Bio Pharma Dive

APRIL 1, 2022

Taysha Gene Therapies is narrowing its research efforts and cutting around 35% of its workforce, the latest in a series of layoffs announced by makers of genetic medicines.

Gene Therapy 281

Gene Therapy Gene Development Genetics 281

Pharmaceutical Technology

APRIL 10, 2023

Aviceda Therapeutics (Aviceda) has entered into a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (QUB) for the development of next-generation glyco-immune therapeutics. Aviceda Glycotech has been created as an oncology-focused spin-off company from Aviceda Therapeutics and Queen’s.

Development 259

Development Life Science Clinical Trials Clinical Trials 259

Bio Pharma Dive

MAY 1, 2023

The deal is a sizable bet on an experimental geographic atrophy drug now under review that could compete with a medicine from Apellis Pharmaceuticals.

Drugs 281

Drugs Development Medicine 281

Pharmaceutical Technology

MAY 4, 2023

Forge Biologics and global life sciences company Labcorp have announced a strategic adeno-associated virus (AAV) gene therapy development and manufacturing collaboration. This will improve accessibility to services for AAV-mediated gene therapy programmes. This will improve accessibility to services for AAV-mediated gene therapy programmes.

Gene Therapy 256

Gene Therapy Gene Development Manufacturing 256

Bio Pharma Dive

AUGUST 22, 2022

After spiking on news of the merger’s close, shares in the ADHD treatment developer fell sharply in trading Monday and again on Tuesday.

Medicine 281

Medicine Marketing Development 281

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Pharmaceutical Technology

APRIL 3, 2023

Ablaze Pharmaceuticals is set to develop a new GPC3-targeted peptide drug candidate for the treatment of liver cancer in China. The agreement allows Ablaze to clinically develop and commercialise the drug in Greater China. The company is licensing the first-in-class drug candidate under an existing deal with RayzeBio.

Development 246

Development Drugs Clinical Development Licensing 246

Pharmaceutical Technology

APRIL 3, 2023

BioNTech has signed exclusive licence and collaboration agreements with Duality Biologics (DualityBio) for the development of two antibody-drug conjugate (ADC) assets for solid tumours. Once developed, the ADCs will join BioNTech’s existing portfolio of oncology products.

Development 246

Development Sales Antibody Manufacturing 246

Bio Pharma Dive

DECEMBER 18, 2024

The company plans to use its new funds to get to “proof of concept” for its medicines. “Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO.

Development 260

Development Medicine Drugs 260

Bio Pharma Dive

APRIL 8, 2024

But many development hurdles still stand in the way of new medicines for the brain. Recent biotech company acquisitions have put emerging schizophrenia treatments in focus.

Medicine 343

Medicine Drugs Development 343

Drug Patent Watch

JANUARY 14, 2025

But how do companies develop these cost-effective alternatives? Generic drug manufacturers are taking a similar approach by developing multiple drugs simultaneously[1]. ”[2] This study not only addressed the ATA’s concerns but also highlighted the power of real-world evidence in generic drug development and regulation.

Generic Drugs 87

Generic Drugs Development Drugs Manufacturing 87

Bio Pharma Dive

DECEMBER 15, 2022

Relyvrio, a drug developed by Amylyx Pharmaceuticals, is in high demand in ALS clinics across the U.S. Though some patients are already getting it, insurance coverage and out-of-pocket costs remain a source of anxiety.

Doctors 260

Doctors Doctor Medicine Development 260

Drug Patent Watch

DECEMBER 10, 2024

The pharmaceutical industry has undergone significant changes over the past decade, with a growing trend towards outsourcing key aspects of research, development, and manufacturing to third-party vendors. The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48

Manufacturing 96

Manufacturing Development Drugs Compliance 96

Pharmaceutical Technology

MAY 12, 2023

The Technical University of Denmark (DTU) has announced that an international scientific team has developed a CRISPR-based drug candidate that targets E coli directly and leaves the microbiome intact. The division of infectious diseases at Weill Cornell Medicine carried out the work in collaboration with JAFRAL and JMI Laboratories.

Development 246

Development Bacteria Research Drugs 246

Pharmaceutical Technology

MAY 24, 2023

Forge Biologics has joined the public-private collaboration, the Bespoke Gene Therapy Consortium (BGTC), to expedite the development and manufacture of new AAV [adeno-associated virus] gene therapies to treat patients with rare diseases. Shilling was appointed to represent the company on the steering committee of the BGTC.

Gene Therapy 242

Gene Therapy Gene Development Manufacturing 242

Pharmaceutical Technology

FEBRUARY 8, 2024

Despite several ground-breaking developments, pharmaceutical and biotech companies are often reluctant to invest in cell and gene therapy.

Gene Therapy 246

Gene Therapy Gene Medicine Development 246